OCA
SANA icon

Octagon Capital Advisors’s Sana Biotechnology SANA Stock Holding History

Octagon Capital Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-360,800
Closed -$3.61M – 56
2024
Q1 		$3.61M Buy
+360,800
New +$2.7M 0.43% 44

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Octagon Capital Advisors's SANA Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Sana Biotechnology (SANA) in Q2 2024, closing a stake of 360,800 shares — an estimated $3.61M sold.

Octagon Capital Advisors first reported a position in SANA in Q1 2024 and held it in 1 quarter. The position peaked at $3.61M in Q1 2024. 148 funds tracked by Wall St. Rank hold SANA as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Sana Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 360,800 Sana Biotechnology shares in Q2 2024, an estimated $3.61M.
  • Octagon Capital Advisors first reported a position in Sana Biotechnology in Q1 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's Sana Biotechnology position peaked at $3.61M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.